Maxacalcitol

Drug Profile

Maxacalcitol

Alternative Names: 22-oxacalcitriol; OCT; Oxarol

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Chugai Pharmaceutical
  • Developer Chugai Pharmaceutical; Maruho
  • Class Antipsoriatics; Calcium regulators; Dihydroxycholecalciferols
  • Mechanism of Action Vitamin D3 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Ichthyosis; Palmoplantar keratoderma; Palmoplantar pustulosis; Psoriasis; Secondary hyperparathyroidism

Most Recent Events

  • 01 Dec 2016 Chugai Pharmaceutical completes a phase I trial in Secondary hyperparathyroidism (In volunteers) in Japan and Taiwan (JapicCTI153094)
  • 04 Nov 2009 Schering-Plough has been acquired and merged into Merck & Co
  • 25 Nov 2008 Registered for Palmoplantar pustulosis in Japan (Topical, Lotion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top